Literature DB >> 15448191

Transcriptional regulation of the human mu-opioid receptor gene by interleukin-6.

Christine Börner1, Jürgen Kraus, Helmut Schröder, Hermann Ammer, Volker Höllt.   

Abstract

Inflammatory pain is counteracted by a number of physiological processes. For example, opioid receptors, which are present on peripheral terminals of sensory neurons, are activated by endogenous opioids, which are released from immune cells migrating to the inflamed tissue. Earlier data demonstrated that interleukin-6 contributes to such inflammation-induced analgesia. In this report, we demonstrated that interleukin-6 strongly induces mu-opioid receptor mRNA in the human neuroblastoma cell line SH SY5Y, whereas delta-opioid receptor mRNA levels are not influenced. The mRNA increase in these cells is followed by an increase in mu-opioid receptor-specific binding. Using transcription factor decoy oligonucleotides, direct evidence was provided that the up-regulation of mu-opioid receptor mRNA in intact cells is dependent on the transcription factors signal transducers and activators of transcription 1 (STAT1) and STAT3, whereas other transcription factors, such as activator protein-1, nuclear factor (NF)-kappaB, or NF-interleukin-6 are not involved. STAT1 and STAT3 bound to a site located at nucleotide -1583 on the promoter of the human mu-opioid receptor gene, as shown by transient transfection experiments, electrophoretic mobility shift assays, and transcription factor decoy oligonucleotides. A mutation analysis of the 5'-TTCATGGAA-3' STAT1/3 element (palindrome underlined) was performed to determine nucleotide residues that are necessary for the binding of STAT1 and STAT3. It suggested that only the palindromic half sides and the two adjacent central nucleotides are required. Neither mutation of the nucleotides outside the palindrome nor mutation of the central nucleotide affected STAT1/3 binding.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15448191     DOI: 10.1124/mol.104.003806

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  23 in total

Review 1.  Transcriptional and epigenetic regulation of opioid receptor genes: present and future.

Authors:  Li-Na Wei; Horace H Loh
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

Review 2.  Modulation of immune function by morphine: implications for susceptibility to infection.

Authors:  Sabita Roy; Jinghua Wang; Jennifer Kelschenbach; Lisa Koodie; Josephine Martin
Journal:  J Neuroimmune Pharmacol       Date:  2006-03       Impact factor: 4.147

3.  Sex differences in μ-opioid receptor expression in trigeminal ganglia under a myositis condition in rats.

Authors:  X Zhang; Y Zhang; J Asgar; K Y Niu; J Lee; K S Lee; M Schneider; J Y Ro
Journal:  Eur J Pain       Date:  2013-06-25       Impact factor: 3.931

4.  μ and κ opioid receptor distribution in the monogamous titi monkey (Callicebus cupreus): implications for social behavior and endocrine functioning.

Authors:  B J Ragen; S M Freeman; S A Laredo; S P Mendoza; K L Bales
Journal:  Neuroscience       Date:  2015-01-29       Impact factor: 3.590

5.  Morphine promotes neovascularizing retinopathy in sickle transgeneic mice.

Authors:  Kalpna Gupta; Chunsheng Chen; Gerard A Lutty; Robert P Hebbel
Journal:  Blood Adv       Date:  2019-04-09

Review 6.  Sex differences in innate immunity and its impact on opioid pharmacology.

Authors:  Hillary H Doyle; Anne Z Murphy
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

7.  The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells.

Authors:  Randall L Davis; Daniel J Buck; Neda Saffarian; Craig W Stevens
Journal:  J Neuroimmunol       Date:  2007-05-01       Impact factor: 3.478

8.  Inducible expression of functional mu opioid receptors in murine dendritic cells.

Authors:  Zheng-Hong Li; Niansheng Chu; Li-Dong Shan; Shan Gong; Qi-Zhang Yin; Xing-Hong Jiang
Journal:  J Neuroimmune Pharmacol       Date:  2009-02-03       Impact factor: 4.147

9.  OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.

Authors:  Gabor Oroszi; Raymond F Anton; Stephanie O'Malley; Robert Swift; Helen Pettinati; David Couper; Qiaoping Yuan; David Goldman
Journal:  Alcohol Clin Exp Res       Date:  2008-11-25       Impact factor: 3.455

10.  Neonatal administration of thimerosal causes persistent changes in mu opioid receptors in the rat brain.

Authors:  Mieszko Olczak; Michalina Duszczyk; Pawel Mierzejewski; Teresa Bobrowicz; Maria Dorota Majewska
Journal:  Neurochem Res       Date:  2010-08-28       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.